The involvement of noradrenergic transmission in the morphine-induced locomotor hyperactivity in mice withdrawn from repeated morphine treatment

British Journal of Pharmacology

Volumn 126, Issue 7, 1999, Pages 1609-1619

  Airio, Juha ^a   Ahtee, Liisa ^a  

^a NONE

Author keywords

Behavioural sensitization; Brain noradrenaline release; Locomotor activity; Morphine challenge; Morphine withdrawal; Striatal dopamine release; 2 adrenoceptors

Indexed keywords

3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; DOPAMINE; HOMOVANILLIC ACID; IDAZOXAN; MORPHINE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; SENSITIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

EID: 0032961248     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702485     Document Type: Article

References (68)

1. ACQUAS, E. & DI CHIARA, G. (1992). Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate withdrawal. J. Neurochem., 58, 1620-1625.
2. AHTEE, L. (1973). Catalepsy and stereotyped behaviour in rats treated chronically with methadone: relation to brain homovanillic acid content. J. Pharm. Pharmacol., 25, 649-651.
3. AHTEE, L. (1978). Effects of drugs affecting extrapyramidal motor functions on catalepsy and stereotypies induced by narcotic analgesics. In Factors affecting the action of narcotics, ed. Adler, M.L., Manara, L., Samanin, R. pp. 479-494. New York: Raven Press.
4. AHTEE, L., ATTILA, L.M.J. & CARLSON, K.R. (1990). Augmentation of morphine-induced changes in brain monoamine metabolism after chronic naltrexone treatment. J. Pharmacol. Exp. Ther., 255, 803-808.
5. AHTEE, L., ATTILA, L.M.J., CARLSON, K.R. & HAIKALA, H. (1989). Changes in brain monoamine metabolism during withdrawal from chronic oral self-administration of morphine and in response to a morphine challenge dose in the withdrawn state. J. Pharmacol. Exp. Ther., 249, 303-310.
6. AHTEE, L., ATTILA, P., LAUHAKANGAS, V., SOLKINEN, A. & SIPILÄ, J. (1987). The fall of homovanillic acid and 5-hydroxyindoleacetic acid concentrations in brains of mice withdrawn from repeated morphine treatment and their restoration by acute morphine administration. J. Neural Transmission, 68, 63-78.
7. AIRIO, J. & AHTEE, L. (1997). Role of cerebral dopamine and noradrenaline in the morphine-induced locomotor sensitisation in mice. Pharmacol. Biochem. Behav., 58, 379-386.
8. AIRIO, J., ATTILA, M. & AHTEE, L. (1995). Regional differences in cerebral noradrenaline turnover in mice withdrawn from repeated morphine treatment and tolerance to the effects of acute morphine. Pharmacol. Toxicol., 77, 196-203.
9. AIRIO, J., ATTILA, M., LEIKOLA-PELHO, T. & AHTEE, L. (1994). Withdrawal from repeated morphine treatment sensitises mice to the striatal dopamine release enhancing effect of acute morphine. Naunyn-Schmiedeberg's Arch. Pharmacol., 350, 548-554.
10. ATTILA, L.M.J. & AHTEE, L. (1983). Cerebral dopamine and noradrenaline turnover and effects of morphine test dose in rats withdrawn from 20 days' morphine treatment. Med. Biol., 61, 249-257.
11. ATTILA, L.M.J. & AHTEE, L. (1984). Retardation of cerebral dopamine turnover after morphine withdrawal and its enhanced acceleration by acute morphine administration in rats. Naunyn-Schmiedeberg's Arch. Pharmacol., 327, 201-207.
12. ATTILA, L.M.J., ETEMADZADEH, E. & AHTEE, L. (1987). Differences in the effects of morphine on the α-methyl-p-tyrosine-induced depletion of dopamine and noradrenaline in various areas of the mouse brain. Pharmacol. Toxicol., 61, 26-32.
13. AYHAN, I.H. (1978). Morphine-induced behavior of mice and its relation to brain catecholamines. In Characteristics and function of opioids, ed. Van Ree, J.M., Terenius, L. pp. 349-350. Amsterdam: Elsevier/North-Holland Biomedical Press.
14. BABBINI, M. & DAVIS, W.M. (1972). Time-dose relationships for locomotor activity effects of morphine after acute or repeated treatment. Br. J. Pharmacol., 46, 213-224.
15. 3H]atipamezole. Eur. J. Pharmacol., 224, 27-38.
16. 3H]RX821002 (2-methoxyidazoxan) binds to alpha 2-adrenoceptor subtypes and a non-adrenoceptor imidazoline binding site in rat kidney. Eur. J. Pharmacol., 316, 359-368.
17. CARROLL, B.J. & SHARP, P.T. (1972). Monoamine mediation of the morphine-induced activation in mice. Br. J. Pharmacol., 46, 124-139.
18. CEASAR, P.M., HAGUE, P., SHARMAN, D.F. & WERDINIUS, B. (1974). Studies on the metabolism of catecholamines in the central nervous system of the mouse. Br. J. Pharmacol., 51, 187-195.
19. CEDARBAUM, J.M. & AGHAJANIAN, G.K. (1977). Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur. J. Pharmacol., 44, 375-385.
20. CHEN, N.-H. & REITH, M.E.A. (1995). Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (±)-8-hydroxy-2-(di-n-propylamino)-tetralin. J. Neurochem., 64, 1585-1597.
21. CHOJNACKA-WOJCIK, E. (1992). Involvement of dopamine autoreceptors in the hypoactivity induced by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice. Pol. J. Pharmacol. Pharm., 44, 135-146.
22. CLOUET, D.H. & RATNER, M. (1970). Catecholamine biosynthesis in brains of rats treated with morphine. Science, 168, 854-855.
23. COOPER, J.R., BLOOM, F.E. & ROTH, R.H. (1996). The biochemical basin of neuropharmacology, pp. 226-292. New York/Oxford: Oxford University Press.
24. CURET, O., DENNIS, T. & SCATTON, B. (1987). Evidence For the involvement of presynaptic alpha-2 adrenoceptors in the regulation of norepinephrine metabolism in the rat brain. J. Pharmacol. Exp. Ther., 240, 327-336.
25. DENNIS, T., L'HEREUX, R., CARTER, C. & SCATTON, B. (1987). Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J. Pharmacol. Exp. Ther., 241, 642-649.
26. ESTLER, C.-J. (1973). Effect of α-and β-adrenergic blocking agents and para-chlorphenylalanine on morphine-and caffeine-stimulated locomotor activity in mice. Psychopharmacol., 28, 261-268.
27. ETEMADZADEH, E. (1993). Cerebral catecholamine depletion in mice withdrawn from repeated morphine treatment and development of tolerance to the enhancing effect of morphine on noradrenaline depletion. J. Pharmacol. Exp. Ther., 266, 749-755.
28. FERNANDES, M., KLUVE, S. & COPER, H. (1977). Quantitative assessment of tolerance to and dependence on morphine in mice. Naunyn-Schmiedeberg's Arch. Pharmacol., 297, 53-60.
29. 2-adrenoceptors on rat central neurons. Eur. J. Pharmacol., 105, 265-272.
30. FUNADA, M., NARITA, M., SUZUKI, T. & MIASAWA, M. (1993). Effect of pretreatment with pertussistoxin on the development of physical dependence on morphine. Naunyn-Schmiedeberg's Arch. Pharmacol., 348, 88-95.
31. 1-receptors in morphine-induced hyperlocomotion in mice. Neurosci. Lett., 169, 1-4.
32. GRENHOFF, J. & SVENSSON, T.H. (1993). Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur. J. Pharmacol., 233, 79-84.
33. HAIKALA, H. (1986). Different changes in striatal dopamine metabolism induced by nicotine in mice kept at different ambient temperatures. Evidence for partly separate metabolic routes of dopamine derived from separate comparfmentations. Naunyn-Schmiedeberg's Arch. Pharmacol., 334, 3873-3876.
34. HAIKALA, H. (1987). Use of a novel type of rotating disc electrode and a flow cell with laminar flow pattern for the electrochemical detection of biogenic monoamines and their metabolites after Sephadex gel Chromatographic purification and high-performance liquid Chromatographic isolation from rat brain. J. Neurochem., 49, 1033-1041.
35. HAVEMANN, U. & KUSCHINSKY, K. (1982). Neurochemical aspects of the opioid-induced 'catatonia'. Neurochem. Int., 4, 199-215.
36. 1-adrenoceptor function. Br. J. Pharmacol., 96, 547-556.
37. 2-adrenoceptors and non-adrenoceptor, imidazoline binding sites in the central nervous system. Br. J. Pharmacol., 109, 831-837.
38. 2-adrenoceptor antagonists block the stimulant effects of cocaine in mice. Life Sci., 50, PL155-PL159.
39. KEHR, W. (1976). 3-methoxytyramine as an indicator of impulse-induced dopamine release in rat brain in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol., 293, 209-215.
40. KEMPF, E., GILL, M., MACK, G. & MANDEL, P. (1976). Effects of acute morphine administration on the catecholamine metabolism of three strains of mice. Psychopharmacology Communications, 2, 241-250.
41. KURIBARA, H. (1995). Modification of morphine sensitization by opioid and dopamine receptor antagonists; evaluation by studying ambulation in mice. Eur. J. Pharmacol., 275, 251-258.
42. 1A autoreceptors modulating serotonin synthesis in the rat brain in vivo. Neurosci. Lett., 218, 111-114.
43. LONGONI, R., SPINA, L. & DI CHIARA, G. (1987). Dopaminergic D-1 receptors: essential role in morphine-induced hypermotility. Psychopharmacol., 93, 401-402.
44. 2-adrenoceptor antagonist, atipamezole, of apomorphine-induced circling in rats with combined unilateral substantia nigra and DSP-4 lesions. Brit. J. Pharmacol., 119, Proceedings Supplement 344P.
45. 1A receptors in the rat brain. Eur. J. Pharmacol., 312, 385-388.
46. 1 adrenergic receptors in mice responding to morphine with sedation or with running fit. Pol. J. Pharmacol. Pharm., 43, 115-119.
47. MIKKOLA, J., PIEPPONEN, T.P. & AHTEE, L. (1995). Repeated morphine treatment induces tolerance to the inhibitory effect of morphine on striatal dopamine release. Analgesia, 1, 582-585.
48. 3H]RX821002 (2-methoxy idazoxan) in the human and rat brains. J. Pharmacol. Exp. Ther., 264, 1187-1197.
49. NISENBAUM, L.K. & ABERCROMBIE, E.D. (1993). Presynaptic alterations associated with enhancement of evoked release and synthesis of norepinephrine in hippocampus of chronically cold-stressed rats. Brain Res., 608, 280-287.
50. PAEZ, X. & LEIBOWITZ, S.F. (1993). Changes in extracellular PVN monoamines and macronutrient intake after idazoxan or fluoxetine injection. Pharmacol. Biocem. Behav., 46, 933-941.
51. PIEPPONEN, T.P., MIKKOLA, J., RUOTSALAINEN, M. & AHTEE, L. (1995). Dose-dependent decrease of dopamine release in the striatum by intrastriatal morphine. Analgesia, 1, 643-646.
52. RACAGNI, G., BRUNO, F., IULIANI, E. & PAOLETTI, R. (1979). Differential sensitivity to morphine-induced analgesia and motor activity in two inbred strains of mice: Behavioral and biochemical correlations. J. Pharmacol. Exp. Ther., 209, 111-116.
53. ROSSETTI, Z.L., CARBONI, S., MELIS, F., NEFF, N.H. & GESSA, G.L. (1990). Locally perfused morphne inhibits striatal DA release: reversal by systemic morphine. Soc. Neurosci. Abstr., 16 part 2, 1047.
54. 2-adrenoceptor agonist. Mol. Pharmacol., 51, 36-46.
55. SALMI, P., MALMGREN, K., SVENSSON, T.H. & AHLENIUS, S. (1998). Stimulation of forward locomotion by SCH-23390 and raclopride in d-amphetamine-treated rats. Naunyn-Schmiedeberg's Arch. Pharmacol., 357, 593-599.
56. 2-adrenoceptors in the regulation of striatal dopaminergic transmission. Eur. J. Pharmacol., 86, 427-433.
57. SHARMAN, D.F. (1969). Glycol metabolites of noradrenaline in brain tissue. Br. J. Pharmacol., 36, 523-534.
58. SHIPPENBERG, T.S., HEIDBREDER, C.H. & LEFEVOUR, A. (1996). Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics. Eur. J. Pharmacol., 299, 33-39.
59. STARKE, K., BOROWSKI, E. & ENDO, T. (1975). Preferential blockade of presynaptic α-adrenoceptors by yohimbine. Eur. J. Pharmacol., 34, 385-388.
60. STOLERMAN, I.P., JOHNSON, C.A., BUNKER, P. & JARVIK, M.E. (1975). Weight loss and shock-elicited aggression as indices of morphine abstinence in rats. Psychopharmacol., 45, 157-161.
61. THOMAS, D.N., NUTT, D. & HOLMAN, R.B. (1994). Regionally specific changes in extracellular noradrenaline following chronic idazoxan as revealed by in vivo microdialysis. Eur. J. Pharmacol., 261, 53-57.
62. TIAN, Y., LOOKINGLAND, K.J. & MOORE, K.E. (1991). Contribution of noradrenergic neurons to 3,4-dihydroxyphenylacetic acid concentrations in the regions of the rat brain containing incertohypothalamic dopaminergic neurons. Brain Res., 555, 135-140.
63. 2A-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices. Naunyn-Schmiedeberg's Arch. Pharmacol., 350, 473-481.
64. WESTERINK, B.H.C. & SPAAN, S.J. (1982a). Estimation of the turnover of 3-methoxytyramine in the rat striatum by HPLC with electrochemical detection: Implications for the sequence in the cerebral metabolism of dopamine. J. Neurochem., 38, 342-347.
65. WESTERINK, B.H.C. & SPAAN, S.J. (1982b). On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain. J. Neurochem., 38, 680-686.
66. WOOD, P.L. (1993). Interrelationships of opioid, dopaminergic, cholinergic, and GABAergic pathways in the central nervous system. In Handbook of experimental pharmacology, vol 104/I; Opioids I. ed. Herz, A. pp. 624-643. Berlin/Heidelberg: Springer.
67. WOOD, P.L., KIM, H.S., STOCKLIN, K. & RAO, T.S. (1988). Dynamics of the striatal 3-MT pool in rat and mouse: species differences as assessed by steady-state measurements and intracerebral dialysis. Life Sci., 42, 2275-2282.
68. 2-adrenergic control of dopamine overflow and metabolism in mouse striatum. Eur. J. Pharmacol., 339, 113-119.